Eledon Pharmaceuticals Inc (NASDAQ:ELDN) does about 389.78K shares in volume on a normal day but saw 811110 shares change hands in the recent trading day. The company now has a market cap of 284.36M USD. Its current market price is $4.76, marking an increase of 8.92% compared to the previous close of $4.37. The 52 week high reached by this stock is $5.54 whilst the lowest price level in 52 weeks is $1.12.
Eledon Pharmaceuticals Inc (ELDN) has a 20-day trading average at $4.40 and the current price is -14.08% off the 52-week high compared with 325.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.62 and its 200-day simple moving average is $2.70. If we look at the stock’s price movements over the week, volatility stands at 10.55%, which decreases to 9.02% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.61 to suggest the stock is neutral.
The consensus objective for the share price is $13.88, suggesting that the stock has a potential upside of 65.71% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 13, 2022 when Cantor Fitzgerald resumed the stock to “Overweight” and issued a price target of between $25 and $15.
The current price level is 8.12%, 31.56%, and 76.24% away from its SMA20, SMA50, and SMA200 respectively, with the ELDN price moving below the 50-day SMA on current market day. Eledon Pharmaceuticals Inc (ELDN) stock is up 18.70% over the week and -10.19% over the past month. Its price is 164.44% year-to-date and 317.54% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of -0.29 above consensus estimates by 0.09. The company’s next earnings report forecasts estimating quarterly EPS at -0.34 and -1.34 for whole year.
To reach the target analysts have set, the stock logically needs to grow 65.71 percent from here.
Outstanding shares total 59.74M with insiders holding 0.04% of the shares and institutional holders owning 42.88% of the company’s common stock. The company has a return on investment of -130.87% and return on equity of -119.41%. The beta has a value of 0.77. Price to book ratio is 2.58.
